MarketCap
Tarsus Pharmaceuticals TARS
$ 68.11
0.98%
Facebook
X
Telegram
Tarsus Pharmaceuticals Operating Cycle | TARS
Quarterly Operating Cycle Tarsus Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.4 | 85.2 | 95.6 | 47.4 | 92.7 | 102 | 110 | 52.2 | 55.6 | 66.4 | 76.8 | 76.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 110 | 47.4 | 78.2 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Sesen Bio
SESN
|
391 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
164 | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
25.5 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
392 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
6.22 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Brickell Biotech
BBI
|
26 | - | -5.38 % | $ 6.06 M | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
107 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
18.6 | - | - | $ 5.78 B |  Niderland |
 |
AbbVie
ABBV
|
350 | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
169 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
98.8 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
402 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
Theratechnologies
THTX
|
456 | - | - | $ 83.9 M |  Canada |
 |
Exelixis
EXEL
|
140 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Gilead Sciences
GILD
|
160 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
86.7 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
Insmed Incorporated
INSM
|
400 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
223 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
19.2 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
Longeveron
LGVN
|
28.6 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
554 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mesoblast Limited
MESO
|
0.01 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Adaptimmune Therapeutics plc
ADAP
|
19.1 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
263 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
70.7 | $ 1.09 | 6.37 % | $ 95 M | USA |